A detailed history of Pro Share Advisors LLC transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 5,518 shares of JANX stock, worth $300,124. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,518
Previous 6,655 17.08%
Holding current value
$300,124
Previous $250,000 7.6%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$35.12 - $64.78 $39,931 - $73,654
-1,137 Reduced 17.08%
5,518 $231,000
Q1 2024

May 08, 2024

BUY
$7.93 - $49.75 $52,774 - $331,086
6,655 New
6,655 $250,000

Others Institutions Holding JANX

About Janux Therapeutics, Inc.


  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $2.27B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.